小脑
医学
多发性骨髓瘤
癌症研究
泛素连接酶
嵌合抗原受体
功能(生物学)
双特异性抗体
免疫疗法
单克隆抗体
临床试验
免疫学
安全概况
泛素蛋白连接酶类
治疗方法
抗体
人性化鼠标
机制(生物学)
抗原
免疫系统
癌症
临床实习
生物信息学
受体
计算生物学
作者
Lorenzo Cani,Roberto Mina,Sagar Lonial
标识
DOI:10.1097/ppo.0000000000000851
摘要
Despite substantial improvements in survival over recent decades, multiple myeloma (MM) remains largely incurable, and most patients ultimately experience relapsed or refractory disease, highlighting the need for novel therapeutic strategies. Immunomodulatory drugs (IMiDs) have transformed MM treatment through direct antitumor and immune-enhancing effects mediated by cereblon modulation, while their ability to stimulate T-cell and NK-cell function has provided a strong rationale for combination with modern immunotherapies, including bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies. More recently, cereblon E3 ligase modulators (CELMoDs), such as iberdomide and mezigdomide, have emerged as next-generation cereblon-targeting agents with enhanced potency, deeper substrate degradation, and activity in lenalidomide- and pomalidomide-resistant settings. Clinical studies have demonstrated promising efficacy and manageable safety profiles across newly diagnosed and relapsed/refractory MM, including in heavily pretreated patients. In parallel, novel degraders such as cemsidomide have shown encouraging preliminary activity, further expanding the therapeutic potential of cereblon-directed approaches in MM. In this review, we aim to summarize the evolution of oral therapies in MM, focusing on the efficacy and safety of next-generation cereblon modulators and emerging cereblon-directed degraders.
科研通智能强力驱动
Strongly Powered by AbleSci AI